Overview
HealthEquity Q3 revenue rises 7% yr/yr, slightly beating analyst expectations
Adjusted EPS for Q3 beats consensus, while net income misses estimates
Company returned $93.7 mln to shareholders via stock repurchases
Outlook
Company expects fiscal year revenue between $1.302 bln and $1.312 bln
HealthEquity projects net income of $197 mln to $205 mln for fiscal year
Company forecasts Adjusted EBITDA of $555 mln to $565 mln for fiscal year
Result Drivers
HSA ASSETS GROWTH - Total HSA assets grew 15% to $34.4 bln, contributing to revenue increase
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$322.16 mln
$321.03 mln (14 Analysts)
Q3 Adjusted EPS
Beat
$1.01
$0.93 (13 Analysts)
Q3 Net Income
Miss
$51.69 mln
$82.04 mln (11 Analysts)
Q3 Adjusted EBITDA
Beat
$141.80 mln
$132.78 mln (14 Analysts)
Q3 Pretax Profit
Miss
$67.53 mln
$110.42 mln (8 Analysts)
Q3 Gross Profit
$228.06 mln
Q3 Operating Expenses
$149.37 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Healthequity Inc is $122.50, about 23.9% above its December 2 closing price of $98.88
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago
Press Release: ID:nGNX8Bvs76
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)